Table 3.

Substudies of the main ScanCLAD study

Donor-specific antibodies in chronic lung allograft dysfunction

PTDM in lung transplantation

Equipotency of tacrolimus and cyclosporine in vivo and in vitro

Quality of life after lung transplantation in Scandinavia

Cytomegalovirus as a risk factor for CLAD and its subtypes BOS and RAS

Imaging in primary graft dysfunction

Clinical pharmacokinetics of once-daily prolonged release tacrolimus in cystic fibrosis compared to non-cystic fibrosis lung transplant recipients

Recovery of RV failure in PAH after lung transplantation

Lung donor characteristics as risk factors for PGD and CLAD

Molecular biomarkers as potential targets for therapeutic strategies after lung transplantation

Correlation of the incidence of acute rejection with the non-invasive blood transcriptional assay (SORT)

Weight-to-height ratio as a predictor for CLAD and overall survival after lung transplantation

Cytokines and inflammatory variables in lung-transplanted recipients

AMR in lung transplantation: treatment and risk factors

CLAD subtypes, BOS and RAS, defined by computed tomography volumetry

AMR antibody-mediated rejection, CLAD chronic lung allograft dysfunction, BOS bronchiolitis obliterans syndrome, PGD primary graft dysfunction, PTDM post-transplantation diabetes mellitus, RAS restrictive allograft syndrome